6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study tested the safety, tolerability and efficacy of lumiracoxib - a COX-2 inhibitor-
in patients with primary knee osteoarthritis or rheumatoid arthritis.